|
Efficacy (95% confidence intervals)
|
---|
Benguela
|
Zaire
|
Lunda Sul
|
---|
DPb
|
ASAQa
|
ALa
|
ASAQa
|
ALa
|
DPb
|
---|
Uncorrected
|
Per-protocol day 28
|
100 (95–100)
|
99 (94–100)
|
92.8 (85–97)
|
82.2 (72–89)
|
90.1 (82–95)
|
100 (95–100)
|
Per-protocol day 42
|
94.6 (87–98)
|
–
|
–
|
–
|
–
|
100 (95–100)
|
Kaplan–Meier estimate day 28
|
100 (100–100)
|
98.9 (97–100)
|
92.7 (88–98)
|
82.1 (75–90)
|
90.1 (84–96)
|
100 (100–100)
|
Kaplan–Meier estimate day 42
|
94.6 (90–99)
|
–
|
–
|
–
|
–
|
100 (100–100)
|
PCR-corrected
|
Per-protocol day 28
|
100 (97–100)
|
100 (97–100)
|
95.5 (89–98)
|
93 (85–97)
|
96.4 (90–99)
|
100 (96–100)
|
Per-protocol day 42
|
100 (96–100)
|
–
|
–
|
–
|
–
|
100 (96–100)
|
Kaplan–Meier estimate day 28
|
100
|
100 (97–100)
|
95.5 (91–100)
|
93.3 (88–99)
|
96.5 (93–100)
|
100
|
Kaplan–Meier estimate day 42
|
100 (96–100)
|
–
|
–
|
–
|
–
|
100
|
- Per-protocol efficacy defined as proportion adequate clinical and parasitological response, Kaplan–Meier estimate calculated from estimate of survival function
- AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
- a28-day follow up
- b42-day follow up